10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 19.34% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 19.34% YoY), while the FY2025 annual figure was $10.5 million, down 16.08% from the prior year.
• Non-Current Deffered Revenue came in at $10.1 million for Q1 2026 at 10x Genomics, down from $10.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q1 2025 to a low of $3.2 million in Q4 2022.
• A 5-year average of $10.3 million and a median of $10.9 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue jumped 178.48% in 2023 and declined 19.34% in 2026, its largest moves.
• 10x Genomics' Non-Current Deffered Revenue stood at $3.2 million in 2022, then surged by 178.48% to $8.8 million in 2023, then soared by 41.97% to $12.5 million in 2024, then decreased by 16.08% to $10.5 million in 2025, then slipped by 3.46% to $10.1 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $10.1 million, $10.5 million, and $10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison